EYEG News and Press, Eyegate Pharmaceuticals Inc. From 05/25/21

AnPac Bio-Medical Science (ANPC) +29% on launching novel Cancer treatment technology and product JV.Pieris Pharmaceuticals (PIRS) +21% on collaboration with Genentech.Ault Global Holdings (DPW) +14% on Q1 results.Taiwan Liposome Company (TLC) +13% as its application for Am...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, investors! We’re back at it again with a look at the biggest pre-market stock movers for Tuesday. Source: Shutterstock Chinese education stocks are on the move today and we’re all still s...

The "Tesla Test" looks for the rare combination of forensic scores that preceded a 40% drop in TSLA stock in a prior ad-hoc study forecasting many other stock declines since. This ongoing test of 22 adverse fundamental forensic and value ratios across four accounting algorithms resume...

Eyegate Pharmaceuticals (EYEG): Q1 Net loss of $2.58M.Cash and cash equivalents of $6.61M.Press Release For further details see: Eyegate Pharmaceuticals reports Q1 results

- PP-001: proof-of-concept study in Austria for dry eye patients expected to initiate in Q3:21; U.S. IND submission planned in Q4:21- -OBG: U.S. IND submission and initiation of Phase 2 dry eye study is planned in Q4:21; proof-of-concept study for persistent epithelial defects e...

WALTHAM, Mass., April 01, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage company developing products for treating inflammatory and immune diseases, today announced that it has appointed K...

Eyegate Pharmaceuticals (EYEG): FY Revenue of $0.01M (-99.6% Y/Y) misses by $0.02M.Cash and cash equivalents were $1.186 million as of December 31, 2020, compared to $3.777 million as of December 31, 2019. Press Release For further details see: Eyegate Pharmaceuticals misses on rev...

WALTHAM, Mass., March 25, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage company developing and commercializing products for treating inflammatory and immune diseases with a focus on the eye a...

- Franz Obermayr, Ph.D. Appointed as Acting Chief Executive Officer, Transitioning From EVP Clinical Development - - Stephen From Elevated from Chief Executive Officer to Executive Chairman - WALTHAM, Mass., Feb. 01, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, In...

Mesoblaston (MESO) +68% after announcing additional results from the DREAM-HF Phase 3 trial.TransEnterix (TRXC) +64%.LM Funding America (LMFA) +49%.Aileron Therapeutics (ALRN) +35%.Bionano Genomics (BNGO) +24% after announcing first publication from the COVID-19 host genome structur...